Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Latest from UK Markey

Although many labs study cancer as an all-or-nothing process, putting all metastable hybrid stages in the same bin, our laboratory at the University of Kentucky is exploring carcinogenesis as a continuum, from initiation through progression to maintenance. This approach has prompted us to focus on the role of epigenetics in cancer development.
Lowell B. Anthony, MD, FACP, sheds light on important data that have shaped the current neuroendocrine tumors treatment paradigm and highlights notable ongoing studies.
Open access to unbiased data repositories of molecular and clinical data will be essential to accelerating future discoveries in precision medicine.
Anthracyclines widely used for a variety of malignancies cause cardiotoxic effects that manifest as cardiomyopathy. Maya E. Guglin, MD, PhD, discusses supportive therapy for these patients.
The natural products produced by microbes found in the environment have led to major therapeutic breakthroughs for a variety of conditions ranging from infectious disease to cancer.
John A. D'Orazio, MD, PhD, associate professor, Department of Pediatrics, College of Medicine, University of Kentucky Markey Cancer Center, discusses ongoing research exploring ultraviolet radiation signature mutations in patients with melanoma.
Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.
The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.
Publication Bottom Border
Border Publication